Skip to main content
Evidence Snapshot

Vasopressin V2 receptor

CHEMBL3766 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3766
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Vasopressin V2 receptor as ChEMBL target CHEMBL3766, mapped to UniProt Q00788. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Vasopressin V2 receptor
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL3766
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q00788
Vasopressin V2 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Vasopressin V2 receptor matters

As of 2026-09-13

Vasopressin V2 receptor is reviewed as Vasopressin V2 receptor (UniProt Q00788); the current evidence base includes 7 approved drugs, 634 compounds, and 75 assays, with lead potency reaching pChEMBL 10.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 634 compounds, and 75 assays for this target. The dominant activity type is IC50. CHEMBL4468523 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL4468523 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Vasopressin V2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q00788, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

634
Total Compounds
75
Total Assays
7
Approved Drugs
IC50: 463.0, KI: 104.0, EC50: 9.0, KD: 45.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4468523
 10.7 EC50 —
No preferred name
CHEMBL1429
 10.5 EC50 Approved
No preferred name
CHEMBL4539370
 10.3 EC50 —
No preferred name
CHEMBL375324
 9.7 Ki —
No preferred name
CHEMBL435323
 9.6 Ki —

Approved Drugs

Structure Compound First Approval
VASOPRESSIN
CHEMBL373742
 2014
MOZAVAPTAN
CHEMBL420762
 2006
CONIVAPTAN
CHEMBL1755
 2005
OXYTOCIN
CHEMBL395429
 1980
DESMOPRESSIN
CHEMBL1429
 1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:24:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3766